SAB BIOTHERAPEUTICS, INC. Increase (Decrease) in Accounts Receivable
SAB BIOTHERAPEUTICS, INC. (SABS) reported Increase (Decrease) in Accounts Receivable of -$5.56 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2025-03-31
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2023-12-31 was $0.00.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2023-09-30 was -$361.74K, a 110.86% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2023-06-30 was -$401.39K.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2023-03-31 was -$4.79M, a 226.95% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2023 was -$5.56M.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2022 was -$2.45M.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2021 was -$12.56M, a 170.75% decline from fiscal 2020.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2020 was $17.75M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$361.74K derived: sum of 2 quarters · filed 2025-03-31 | -$763.12K derived: sum of 3 quarters · filed 2025-03-31 | -$5.56M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$361.74K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$763.12K derived: sum of 2 quarters · filed 2024-11-06 | -$5.56M 10-Q · filed 2024-11-06 | -$12.94M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$401.39K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$5.19M 10-Q · filed 2024-08-08 | -$12.58M derived: sum of 3 quarters · filed 2024-08-08 | -$9.25M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$4.79M 10-Q · filed 2024-05-20 | -$12.18M derived: sum of 2 quarters · filed 2024-05-20 | -$8.85M derived: sum of 3 quarters · filed 2024-05-20 | -$11.02M derived: sum of 4 quarters · filed 2024-05-20 |
| 2022-12-31 | -$7.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$4.06M derived: sum of 2 quarters · filed 2024-03-29 | -$6.23M derived: sum of 3 quarters · filed 2024-03-29 | -$2.45M 10-K · filed 2024-03-29 |
| 2022-09-30 | $3.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $1.16M derived: sum of 2 quarters · filed 2023-11-13 | $4.93M 10-Q · filed 2023-11-13 | $2.73M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$2.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | $1.60M 10-Q · filed 2023-08-21 | -$600.55K derived: sum of 3 quarters · filed 2023-08-21 | -$7.50M derived: sum of 4 quarters · filed 2023-08-21 |
| 2022-03-31 | $3.78M 10-Q · filed 2023-05-15 | $1.57M derived: sum of 2 quarters · filed 2023-05-15 | -$5.32M derived: sum of 3 quarters · filed 2023-05-15 | $193.01K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$2.20M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-04-28 | -$9.10M derived: sum of 2 quarters · filed 2023-04-28 | -$3.58M derived: sum of 3 quarters · filed 2023-04-28 | -$12.56M 10-K/A · filed 2023-04-28 |
| 2021-09-30 | -$6.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$1.38M derived: sum of 2 quarters · filed 2022-11-14 | -$10.36M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $5.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$3.46M 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | -$8.98M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $17.75M 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |